ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.97
0.10%
US Tech 100
19,996.40
-0.65%
S&P 500
5,917.11
0.00%
US Dollar vs CAD
1.39719
0.01%
Bitcoin
97,419.58
3.24%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Sanofi (SAN) Share Price

Sanofi

Sanofi (SAN)

Sagalio Energy Ltd
Sant Uk.10te%
Banco Santander SA
90.36
-0.44
( -0.48% )
Updated: 03:25:06
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
90.36
Bid
90.35
Ask
90.36
Volume
131,744
90.30 Day's Range 90.94
83.28 52 Week Range 106.14
Market Cap
113.189B
Previous Close
90.80
Open
90.44
Last Trade
39
@
90.36
Last Trade Time
03:25:00
Financial Volume
-
VWAP
-
Average Volume (3m)
1,549,285
Shares Outstanding
1,252,640,466
Dividend Yield
12.26%
PE Ratio
21.07
Earnings Per Share (EPS)
4.31
Revenue
43.07B
Net Profit
5.4B

About Sanofi

Sector
Health & Allied Services,nec
Industry
Pharmaceutical Preparations
Website
www.sanofi.com
Headquarters
Paris, Paris, Fra
Founded
1994
Sanofi is listed in the Health & Allied Services sector of the Euronext with ticker SAN. The last closing price for Sanofi was 90.80 €. Over the last year, Sanofi shares have traded in a share price range of 83.28 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares outstanding. The market capitalization of Sanofi is 113.74 € billion. Sanofi has a price to earnings ratio (PE ratio) of 21.07.

Ask ADVFN Intelligence (AI)

SAN Latest News

More News

Sanofi: Information concerning the total number of voting rights and shares - October 2024

Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

20 hours ago
UK Regulatory

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

20 hours ago
UK Regulatory

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le...

November 15 2024
UK Regulatory

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive...

November 15 2024
GlobeNewswire Inc.

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...

November 15 2024
UK Regulatory

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation...

November 14 2024
UK Regulatory

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat...

November 14 2024
UK Regulatory

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination...

November 14 2024
GlobeNewswire Inc.

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in the EU as the first and only medicine for young...

November 06 2024
UK Regulatory

Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE pour le traitement de l’œsophagite à éosinophiles du jeune enfant

Communiqué de presse : Dupixent, premier et seul médicament approuvé dans l’UE pour le traitement de l’œsophagite à éosinophiles du jeune enfant Dupixent, premier et seul médicament approuvé dans...

November 06 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3-3.2133676092593.3694.490.17181427491.84798315DE
4-8.05-8.1800630017398.41101.990.17161980095.67021175DE
12-10.28-10.2146263911100.64106.1490.171549285100.17713939DE
260.790.88199173830589.57106.1485.94147653196.02560974DE
525.366.3058823529485106.1483.28144621792.79867252DE
1560.971.0851325651689.39106.6676.45175830092.46885427DE
2608.19.8468271334882.26106.6667.65195154489.31660651DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALNEVNeovacs
0.0003 €
(50.00%)
5k
ATODSAtos SE
0.0055 €
(34.15%)
10.58M
SOISOITEC
76.50 €
(20.47%)
173.91k
HYLHyloris Pharmaceuticals SA
5.90 €
(13.90%)
34.1k
ALINSIntrasense
0.314 €
(12.54%)
116.27k
EBUSEbusco Holding NV
0.92 €
(-24.96%)
1.4M
VACBSPierre & Vacances
0.048 €
(-14.29%)
427
EMGDSEuromedis DS
0.0088 €
(-12.00%)
2.65k
ALVETTheraVet SA
0.0802 €
(-10.89%)
28.77k
ALAIRGroupe Airwell
1.43 €
(-9.49%)
1.57k
ATODSAtos SE
0.0055 €
(34.15%)
10.58M
ALVERVergnet
0.0054 €
(12.50%)
7.63M
ALTDTonner Drones
0.01 €
(8.70%)
5.87M
BCPBanco Comercial Portugues SA
0.4403 €
(0.11%)
3.89M
ATOAtos SE
0.1779 €
(-7.58%)
2.66M

Discussion

View Full Feed
Minddoc7 Minddoc7 5 minutes ago
https://www.ccn.com/news/crypto/coinbase-brian-armstrong-crypto-czar-charles-hoskinson/
COIN
Seminole Red Seminole Red 6 minutes ago
good job
cowtown jay cowtown jay 8 minutes ago
How much longer can it be before we start to see detailed stock quotes on this site (advfn) again? So many pieces of the puzzle are starting to be displayed, they have got to be near the point where they are snapped together. We've got to be generating revenue by now.
aniyahsbednar aniyahsbednar 11 minutes ago
Official Website... https://cutt.ly/qeKQMuOM

VitalRize Male Enhancement is a cutting-edge supplement designed to help men regain their stamina, boost testosterone levels, and improve overall confidence. With a blend of natural and clinically tested ingredients, VitalRize offers a holi
aniyahsbednar aniyahsbednar 25 minutes ago
Official Website... https://cutt.ly/2eKQSgxD

Green Regimen Energy and Focus is a dietary supplement designed to enhance energy levels and improve mental focus naturally. Crafted with clean, plant-based ingredients, it is often marketed as a solution for those looking to maintain peak
meshcan meshcan 25 minutes ago
Great investment in R&D. Nasrat has said they will only develop the big drugs who have $1B+ annual sale. So we should see our pipeline get better and better.
ELTP
MoneyMaker111 MoneyMaker111 26 minutes ago
GME to close at or above $30 todayyy?

$GME ( Hyper Bullish / Apish )
#GME ( Hyper Bullish / Apish )
GME
infamous infamous 27 minutes ago
thats funny. on otcmarkets they talk about affordable housing. thats a euphomism for cheap homes in getto areas. 100% sure on that description IMO
ATWT
Golfbum22 Golfbum22 46 minutes ago
Hey

Pauljon4

Your village people are calling

They are missing their anger management idiot

Please grow up and do your research before you think you are smarter than anyone here.

Show some respect and stop worrying about pric
FNMA
PC retired PC retired 46 minutes ago
"Entergy" is a real business, and a big one. All the supposed distributors use the name of a real world business with added or subtracted terms, purely intended to deceive. On another note, how is Mr Szilard's install doing?, we have not heard from him in quite a while- we demand an update!!
FLCX
NotSure2 NotSure2 47 minutes ago
Lol, a judge would not be waiting for approval or not of a company before rendering his/her/zer/their etc... judgment.

The worrying part is this:

Since KG is now (always been, deep state establishment) "an ennemy" of Donald Trump, KG now falls into "allie" of the democr
NWBO
DDA DDA 53 minutes ago
Some smaller amounts going through ... someone is silently pilling up
STGZ
The Danish Dude The Danish Dude 55 minutes ago
I have gone down the alley of dendritic cells and trying to look at alternatives for that time, for a dendritic cell vaccine, that in any way could align with the data in the clinical trial and the results and process covered in the article.

DocLee raises good questions. I have ping-p
NWBO
SkeBallLarry SkeBallLarry 56 minutes ago
Matthew Whitaker is a Great pick Steve Bannon sure is happy about it .. !!
The ELTP King The ELTP King 57 minutes ago
Nasrat promised "at least" two filings by the end of 2024 which means two positive BE studies.

Both BE studies failed.

Now he did say "at least" two filing so maybe the third BE study will actually pass?

Sure would be nice to get another BE or two up to t
ELTP
236T568 236T568 57 minutes ago
BREAKING:

Today’s launch by Russia of an intercontinental ballistic missile against Ukraine is the first time ever an ICBM has been launched at another state in a war.

https://x.com/visegrad24/status/1859515908172960221
TommyJ7651 TommyJ7651 58 minutes ago
I don't think asking Paul about future equity financings will yield much substance. It's not like the guy has a crystal ball and he can tell us exactly how future financing rounds will emerge or what situations we might find ourselves in. He will most likely tell us the same old story about them try
FFMGF
benz280e benz280e 59 minutes ago
Dung_Fart,

Who operates with self appointed importance.

Has spoken, all should take heed...
GDVM
The ELTP King The ELTP King 59 minutes ago
So not only is Nasrat hurting Elite with his Mikah nonsense, he's hurting Elite with his warrant nonsense as well.

The reason warrants are recorded as a liability because it shows the fair value loss the company is realizing during the fiscal period by issuing shares at current share
ELTP
The ELTP King The ELTP King 1 hour ago
Do you have a learning disability?

They can't FREAKING buy ELTP because their brokerages don't allow it.

Tell everyone you know to tell 10 people to buy $100+ we can start a new MOASS like GME
ELTP GME

Your Recent History

EU
SAN
Sanofi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved